Herein, we elucidated the clinical and immunologic associations of highly elevated ADA levels with outcomes at 3 weeks after Atezo/Bev treatment (cycle 2 day 1 [C2D1]) in patients with advanced HCC. Here, ADA is linked to hepatocellular carcinoma.